Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 0.5% during the 1st quarter, Holdings Channel.com reports. The fund owned 6,357 shares of the medical research company’s stock after buying an additional 33 shares during the period. Gilman Hill Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $3,695,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. V Square Quantitative Management LLC acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $187,000. Dark Forest Capital Management LP purchased a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $632,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $2,679,000. Certified Advisory Corp bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth $93,000. Finally, Consolidated Portfolio Review Corp increased its stake in shares of Thermo Fisher Scientific by 30.2% in the third quarter. Consolidated Portfolio Review Corp now owns 634 shares of the medical research company’s stock worth $321,000 after buying an additional 147 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, April 25th. The Goldman Sachs Group boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Finally, Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $607.94.

View Our Latest Stock Report on Thermo Fisher Scientific

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,873,516.56. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO stock traded down $8.14 during trading on Tuesday, hitting $557.81. The company had a trading volume of 446,302 shares, compared to its average volume of 1,505,296. The firm has a market capitalization of $212.93 billion, a price-to-earnings ratio of 36.30, a P/E/G ratio of 2.63 and a beta of 0.79. The business has a 50 day moving average of $574.26 and a 200 day moving average of $561.83. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.